Herold Advisors Inc. Decreases Stock Position in Amgen Inc. (NASDAQ:AMGN)

Herold Advisors Inc. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 9.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,874 shares of the medical research company’s stock after selling 200 shares during the quarter. Herold Advisors Inc.’s holdings in Amgen were worth $540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. OFI Invest Asset Management purchased a new position in shares of Amgen in the third quarter valued at $26,000. Briaud Financial Planning Inc purchased a new position in shares of Amgen in the third quarter valued at $26,000. BOK Financial Private Wealth Inc. purchased a new position in shares of Amgen in the fourth quarter valued at $29,000. Providence Capital Advisors LLC purchased a new position in shares of Amgen in the third quarter valued at $30,000. Finally, Planned Solutions Inc. purchased a new position in shares of Amgen in the fourth quarter valued at $30,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Truist Financial reiterated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Raymond James started coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Finally, SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Trading Up 0.2 %

Shares of NASDAQ AMGN traded up $0.60 during midday trading on Friday, reaching $269.98. The company had a trading volume of 2,436,947 shares, compared to its average volume of 2,822,655. The firm’s fifty day moving average price is $275.10 and its 200-day moving average price is $281.45. The stock has a market cap of $144.81 billion, a PE ratio of 21.62, a price-to-earnings-growth ratio of 2.54 and a beta of 0.58. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.09 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.